TY - JOUR
T1 - Germline BAP1 mutations predispose to renal cell carcinomas
AU - Popova, Tatiana
AU - Hebert, Lucie
AU - Jacquemin, Virginie
AU - Gad, Sophie
AU - Caux-Moncoutier, Virginie
AU - Dubois-D'Enghien, Catherine
AU - Richaudeau, Bénédicte
AU - Renaudin, Xavier
AU - Sellers, Jason
AU - Nicolas, André
AU - Sastre-Garau, Xavier
AU - Desjardins, Laurence
AU - Gyapay, Gabor
AU - Raynal, Virginie
AU - Sinilnikova, Olga M.
AU - Andrieu, Nadine
AU - Manié, Elodie
AU - De Pauw, Antoine
AU - Gesta, Paul
AU - Bonadona, Valérie
AU - Maugard, Christine M.
AU - Penet, Clotilde
AU - Avril, Marie Françoise
AU - Barillot, Emmanuel
AU - Cabaret, Odile
AU - Delattre, Olivier
AU - Richard, Stéphane
AU - Caron, Olivier
AU - Benfodda, Meriem
AU - Hu, Hui Han
AU - Soufir, Nadem
AU - Bressac-De Paillerets, Brigitte
AU - Stoppa-Lyonnet, Dominique
AU - Stern, Marc Henri
N1 - Funding Information:
We are grateful to the family members who participated in this study. The authors would like to thank S. Chanock, C. Houdayer, A. Vincent-Salomon, and E. Heard for helpful discussions; R. Lebofsky and A. Holmes for reviewing the manuscript; M.C. King, S. Giraud, L. Venat, D. Joly, D. Chauveau, and S. Piperno-Neumann for access to individual samples; D. Bellanger, O. Mariani, M. de Lichy, M. Mary, A. Riffault, B. Grandchamp, L. Thomas, and M. Belotti for their contributions; M. Sahbatou and E. Génin for initial genetic studies; the NGS (A.N., P. Legoix-Né) and Sanger (L. Trémolet) platforms; P. Fanen and L. Golmard for help in Exontrap assays; and A. Renier and N. Amirouchene Angelozzi for providing cell lines. This project was supported by grants from Comité de Paris de la Ligue Nationale Contre le Cancer, l’Association pour la Recherche sur le Cancer (ARC), l’Institut National du Cancer (INCa), le Cancéropole Région Ile-de-France, and the Institut Curie Translational department. T.P. was supported by INCa, L.H. by the Translational department and the Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la Recherche (MERNT), and V.J. by ARC. The NGS platform was supported by grants from Canceropôle Ile de France and Région Ile de France. The EMMA technology is dependent on Curie Institute/CNRS/University Pierre et Marie Curie joint patents. D.S.-L. is a shareholder of Fluigent.
PY - 2013/6/6
Y1 - 2013/6/6
N2 - The genetic cause of some familial nonsyndromic renal cell carcinomas (RCC) defined by at least two affected first-degree relatives is unknown. By combining whole-exome sequencing and tumor profiling in a family prone to cases of RCC, we identified a germline BAP1 mutation c.277A>G (p.Thr93Ala) as the probable genetic basis of RCC predisposition. This mutation segregated with all four RCC-affected relatives. Furthermore, BAP1 was found to be inactivated in RCC-affected individuals from this family. No BAP1 mutations were identified in 32 familial cases presenting with only RCC. We then screened for germline BAP1 deleterious mutations in familial aggregations of cancers within the spectrum of the recently described BAP1-associated tumor predisposition syndrome, including uveal melanoma, malignant pleural mesothelioma, and cutaneous melanoma. Among the 11 families that included individuals identified as carrying germline deleterious BAP1 mutations, 6 families presented with 9 RCC-affected individuals, demonstrating a significantly increased risk for RCC. This strongly argues that RCC belongs to the BAP1 syndrome and that BAP1 is a RCC-predisposition gene.
AB - The genetic cause of some familial nonsyndromic renal cell carcinomas (RCC) defined by at least two affected first-degree relatives is unknown. By combining whole-exome sequencing and tumor profiling in a family prone to cases of RCC, we identified a germline BAP1 mutation c.277A>G (p.Thr93Ala) as the probable genetic basis of RCC predisposition. This mutation segregated with all four RCC-affected relatives. Furthermore, BAP1 was found to be inactivated in RCC-affected individuals from this family. No BAP1 mutations were identified in 32 familial cases presenting with only RCC. We then screened for germline BAP1 deleterious mutations in familial aggregations of cancers within the spectrum of the recently described BAP1-associated tumor predisposition syndrome, including uveal melanoma, malignant pleural mesothelioma, and cutaneous melanoma. Among the 11 families that included individuals identified as carrying germline deleterious BAP1 mutations, 6 families presented with 9 RCC-affected individuals, demonstrating a significantly increased risk for RCC. This strongly argues that RCC belongs to the BAP1 syndrome and that BAP1 is a RCC-predisposition gene.
UR - http://www.scopus.com/inward/record.url?scp=84878846119&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2013.04.012
DO - 10.1016/j.ajhg.2013.04.012
M3 - Article
C2 - 23684012
AN - SCOPUS:84878846119
SN - 0002-9297
VL - 92
SP - 974
EP - 980
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 6
ER -